Presentation Date/Time: Saturday, June 5 from 2:00 PM - 6:00 PM | |
Poster Title: Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy | |
Abstract Number: #1052 (Poster Board 23E) | |
Location: S Hall A2 | |
Presentation Date/Time: Monday, June 7 from 8:00 AM - 12:00 PM | |
Poster Title: A double-blind, randomized, placebo-controlled Phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC) | |
Abstract Number: #TPS128 (Trials in Progress Poster Session) | |
Location: S Hall A2 | |
Presentation Date/Time: Monday, June 7 from 8:00 AM - 12:00 PM | |
Poster Title: ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL) | |
Abstract Number: #TPS298 (Trials in Progress Poster Session) | |
Location: S Hall A2 | |
